RETA Annual CFO
-$204.27 M
+$31.43 M+13.34%
31 December 2022
Summary:
As of January 24, 2025, RETA annual cash flow from operations is -$204.27 million, with the most recent change of +$31.43 million (+13.34%) on December 31, 2022. During the last 3 years, it has risen by +$46.88 million (+18.67%).RETA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RETA Quarterly CFO
-$69.93 M
+$11.52 M+14.15%
30 June 2023
Summary:
As of January 24, 2025, RETA quarterly cash flow from operations is -$69.93 million, with the most recent change of +$11.52 million (+14.15%) on June 30, 2023. Over the past year, it has dropped by -$20.81 million (-42.36%).RETA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RETA TTM CFO
-$248.34 M
-$20.81 M-9.14%
30 June 2023
Summary:
As of January 24, 2025, RETA TTM cash flow from operations is -$248.34 million, with the most recent change of -$20.81 million (-9.14%) on June 30, 2023. Over the past year, it has increased by +$24.06 million (+8.83%).RETA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RETA Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.3% | -42.4% | +8.8% |
| 3 y3 years | +18.7% | +64.3% | +41.8% |
| 5 y5 years | -145.3% | -175.2% | +1.1% |
RETA Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | +960.6% | -1981.3% | +2742.7% |
Reata Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | -$69.93 M(-14.1%) | -$248.34 M(+9.1%) |
| Mar 2023 | - | -$81.45 M(+61.5%) | -$227.53 M(+11.4%) |
| Dec 2022 | -$204.27 M(-13.3%) | -$50.43 M(+8.4%) | -$204.27 M(-26.2%) |
| Sept 2022 | - | -$46.53 M(-5.3%) | -$276.77 M(+1.6%) |
| June 2022 | - | -$49.12 M(-15.6%) | -$272.40 M(+9.5%) |
| Mar 2022 | - | -$58.19 M(-52.7%) | -$248.88 M(+5.6%) |
| Dec 2021 | -$235.70 M(-26.9%) | -$122.93 M(+191.6%) | -$235.70 M(+49.3%) |
| Sept 2021 | - | -$42.16 M(+64.7%) | -$157.91 M(+1.3%) |
| June 2021 | - | -$25.60 M(-43.1%) | -$155.84 M(-52.2%) |
| Mar 2021 | - | -$45.01 M(-0.3%) | -$326.18 M(+1.2%) |
| Dec 2020 | -$322.34 M(+28.3%) | -$45.14 M(+12.6%) | -$322.34 M(-24.4%) |
| Sept 2020 | - | -$40.09 M(-79.5%) | -$426.57 M(-0.1%) |
| June 2020 | - | -$195.93 M(+375.9%) | -$426.82 M(+61.9%) |
| Mar 2020 | - | -$41.17 M(-72.4%) | -$263.59 M(+5.0%) |
| Dec 2019 | -$251.15 M(+199.8%) | -$149.38 M(+270.3%) | -$251.15 M(+80.3%) |
| Sept 2019 | - | -$40.34 M(+23.3%) | -$139.27 M(+45.4%) |
| June 2019 | - | -$32.71 M(+13.8%) | -$95.80 M(+8.3%) |
| Mar 2019 | - | -$28.73 M(-23.4%) | -$88.49 M(+5.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$83.78 M(+0.6%) | -$37.50 M(-1293.4%) | -$83.78 M(+18.0%) |
| Sept 2018 | - | $3.14 M(-112.4%) | -$71.02 M(-23.8%) |
| June 2018 | - | -$25.41 M(+5.8%) | -$93.19 M(+9.4%) |
| Mar 2018 | - | -$24.02 M(-2.9%) | -$85.22 M(+2.4%) |
| Dec 2017 | -$83.26 M(+332.3%) | -$24.73 M(+30.0%) | -$83.26 M(+19.5%) |
| Sept 2017 | - | -$19.03 M(+9.2%) | -$69.66 M(+48.5%) |
| June 2017 | - | -$17.43 M(-21.0%) | -$46.91 M(+11.3%) |
| Mar 2017 | - | -$22.06 M(+98.1%) | -$42.13 M(+118.8%) |
| Dec 2016 | -$19.26 M(-56.8%) | -$11.14 M(-399.6%) | -$19.26 M(-6.8%) |
| Sept 2016 | - | $3.72 M(-129.4%) | -$20.67 M(-41.4%) |
| June 2016 | - | -$12.66 M(-1649.2%) | -$35.24 M(+0.5%) |
| Mar 2016 | - | $817.00 K(-106.5%) | -$35.07 M(-21.4%) |
| Dec 2015 | -$44.62 M(-49.7%) | -$12.54 M(+15.5%) | -$44.62 M(+39.1%) |
| Sept 2015 | - | -$10.86 M(-13.0%) | -$32.08 M(+51.2%) |
| June 2015 | - | -$12.48 M(+42.9%) | -$21.22 M(+142.9%) |
| Mar 2015 | - | -$8.74 M | -$8.74 M |
| Dec 2014 | -$88.63 M(+28.5%) | - | - |
| Dec 2013 | -$68.95 M | - | - |
FAQ
- What is Reata Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Reata Pharmaceuticals?
- What is Reata Pharmaceuticals annual CFO year-on-year change?
- What is Reata Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Reata Pharmaceuticals?
- What is Reata Pharmaceuticals quarterly CFO year-on-year change?
- What is Reata Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Reata Pharmaceuticals?
- What is Reata Pharmaceuticals TTM CFO year-on-year change?
What is Reata Pharmaceuticals annual cash flow from operations?
The current annual CFO of RETA is -$204.27 M
What is the all time high annual CFO for Reata Pharmaceuticals?
Reata Pharmaceuticals all-time high annual cash flow from operations is -$19.26 M
What is Reata Pharmaceuticals annual CFO year-on-year change?
Over the past year, RETA annual cash flow from operations has changed by +$31.43 M (+13.34%)
What is Reata Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of RETA is -$69.93 M
What is the all time high quarterly CFO for Reata Pharmaceuticals?
Reata Pharmaceuticals all-time high quarterly cash flow from operations is $3.72 M
What is Reata Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, RETA quarterly cash flow from operations has changed by -$20.81 M (-42.36%)
What is Reata Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of RETA is -$248.34 M
What is the all time high TTM CFO for Reata Pharmaceuticals?
Reata Pharmaceuticals all-time high TTM cash flow from operations is -$8.74 M
What is Reata Pharmaceuticals TTM CFO year-on-year change?
Over the past year, RETA TTM cash flow from operations has changed by +$24.06 M (+8.83%)